Understanding Stathmin-2’s Impact on ALS Motor and Sensory Denervation: Cathleen M. Lutz, PhD
December 18th 2023The vice president of the Rare Disease Translational Center at the Jackson Laboratory discussed results from a recently published study reinforcing stathmin-2 as a potential therapeutic strategy for ALS. [WATCH TIME: 4 minutes]
High-Efficacy Disease-Modifying Therapies for Multiple Sclerosis
December 18th 2023Jason Freeman, MD, MBA, and Abby Rogers, DMSc, PA-C, MPAS, discuss a study presented at ACTRIMS 2023 on high-efficacy disease-modifying therapies for treatment-naïve patients with multiple sclerosis. Sponsored by Novartis.
Neurostimulation and Targeted Treatment Delivery in Epilepsy Care: Martha Morrell, MD
December 17th 2023The clinical professor of neurology at Stanford University School of Medicine talked about the collaboration of Rapport leveraging NeuroPace’s data analysis capabilities to study the target delivery of a therapy for focal epilepsy. [WATCH TIME: 5 minutes]
Potential Role of BHV-7000 Among Antiseizure Medications: Irfan Qureshi, MD
December 15th 2023The chief medical officer at Biohaven provided context on how BHV-7000 may be used with other antiseizure medications as well as what changes in spectral power tell about the agent. [WATCH TIME: 4 minutes]
Understanding the Microglial Immunologic Sex Differences in Alzheimer Disease: Feixiong Cheng, PhD
December 15th 2023The assistant professor at Cleveland Clinic discussed findings from a recently published study that provided insights on the understanding of the molecular basis for female predominance in Alzheimer disease. [WATCH TIME: 3 minutes]
Blurring the Lines Between Acute and Prevention Migraine Treatment: Andrea S. Synowiec, DO, FAAN
December 14th 2023The system vice chair for the department of neurology at Allegheny Health Network discussed the shift in migraine treatment over the past few years with the approval of new therapies and allowing patients more options for their health. [WATCH TIME: 4 minutes]
Understanding the Treatment Benefits of Potassium Channel Activator BHV-7000: Irfan Qureshi, MD
December 12th 2023The chief medical officer at Biohaven provided clinical insight on the mechanism of action of BHV-7000, an antiseizure medication, and its supportive phase 1 data. [WATCH TIME: 4 minutes]
A Real-World Look at the Prolonged Efficacy of Fenfluramine in Dravet Syndrome: Derek Ems, MPH, CPHQ
December 10th 2023The health economics outcomes research specialist at UCB talked about a retrospective analysis assessing the persistence of fenfluramine (Fintepla) in Dravet syndrome over 12 months, compared with valproate and levetiracetam. [WATCH TIME: 4 minutes]
Insights From Comprehensive Research on Epilepsy and Cognitive Decline: Ifrah Zawar, MD
December 8th 2023The assistant professor of neurology at the University of Virginia talked about findings from a comprehensive study on epilepsy and mild cognitive impairment, which was recently presented at AES 2023. [WATCH TIME: 5 minutes]
Tackling Inflammation With Innovative Alzheimer Disease Treatments: Stanley H. Appel, MD
December 7th 2023The director of the Ann Kimball and John W. Johnson Center for Cellular Therapeutics at Houston Methodist Hospital talked about the phase 2 study assessing low-dose COYA 301 in mild-to-moderate Alzheimer disease and the focus on inflammation in this patient population. [WATCH TIME: 5 minutes]
Looking Back on the Latest Advancements in Acute Migraine Treatment: Andrea S. Synowiec, DO, FAAN
December 7th 2023The system vice chair for the department of neurology at Allegheny Health Network talked about the latest preventive and acute treatment options for patients with migraine as well as the progress of research in recent months. [WATCH TIME: 3 minutes]